New pricing policy based on an analysis of populations’ ability to pay in key out-of-pocket markets

AstraZeneca has a new pricing policy for its respiratory and cardiovascular disease products in certain key out-of-pocket markets in scope, based on an ability-to-pay analysis.

Summary  

  • What: AstraZeneca’s International Region business division has conducted an in-depth ability-to-pay analysis on existing products in certain countries. This has shaped the division’s new pricing policy. AstraZeneca has also created an internal Affordability Centre of Excellence, which has a regional team tasked with maximising patient access and affordability.
  • Change: This work has allowed AstraZeneca to redefine its pricing policy and pricing strategy, and start to address access and affordability concerns in these markets.
  • Details: The company has also set up a portal to train staff on its new pricing strategy and how to integrate it into their processes.
  • Scope: respiratory and cardiovascular disease products in specific out-of-pocket markets in scope

Looking closer

AstraZeneca’s International Region business division has conducted an in-depth ability-to-pay analysis in some of its key out-of-pocket markets. This has shaped the division’s new pricing policy, which now takes account of affordability in these markets. The analysis will continue to shape price adjustments for respiratory and cardiovascular disease products in these markets.

AstraZeneca has also created an internal Affordability Centre of Excellence, which has a regional team to maximise patient access and affordability. One of its key roles is to integrate an ability-to-pay analysis into everyday business practice. The company has also set up a portal to train staff on its new pricing strategy and how to integrate it into their processes.

This work has allowed AstraZeneca to redefine its emerging pricing policy and pricing strategy, and start to address access and affordability concerns in these markets.

Sign up to receive updates about our work.